One main reason for increasing insulin prices is rebates. During the April 10, 2019 United States House Energy and Commerce Committee hearing titled “Priced Out of a Lifesaving Drug: getting Answers on the Rising Cost of Insulin” manufacturers, pharmacy benefit managers (PBMs), and congressional representatives discussed the effects rebates were having on prices. Currently, manufacturers pay rebates to health plans or PBMs in exchange for formulary access, which is a major reason we see manufacturer net pricing declining but list prices increasing.
As the drug price debate grows in momentum, we are now starting to hear more about the spike in the costs of insulin. Why? According to the CDC, more than 100 million US adults are now living with diabetes or prediabetes. Each year, 1.4 million Americans are diagnosed with diabetes, while approximately 6 million Americans with diabetes use a form of insulin. With so many people impacted by the growing prevalence of the chronic disease, insulin has become a trending topic in the discussion about high drug costs.
One main reason for increasing insulin prices is rebates. During the April 10, 2019 United States House Energy and Commerce Committee hearing titled “Priced Out of a Lifesaving Drug: getting Answers on the Rising Cost of Insulin” manufacturers, pharmacy benefit managers (PBMs), and congressional representatives discussed the effects rebates were having on prices. Currently, manufacturers pay rebates to health plans or PBMs in exchange for formulary access, which is a major reason we see manufacturer net pricing declining but list prices increasing.
Thus far, Congress has been active with insulin pricing. In addition to the Congressional Diabetes Caucus’ 2018 Report on Insulin, Congress has 2 bills on point: the Affordable Insulin Act of 2019 proposes to allow for the importation of affordable and safe insulin by wholesale distributors, pharmacies, and individuals, while the Insulin Access for All Act of 2019 proposes to eliminate cost sharing with respect to coverage of insulin as a covered Medicare Part D drug or as a covered outpatient drug under the Medicaid program.
These bills follow in the footsteps of Nevada’s trendsetting approach to drug price transparency. In 2017, the state’s first-in-the-nation insulin price transparency law targeted diabetes products and required PBMs and manufacturers to disclose pricing and rebate information, among other things. In 2018, the manufacturing lobby dropped its legal opposition to the law, as it stated that Nevada’s adopted regulations resolved outstanding concerns.
The FDA, which has been taking an aggressive approach in attempting to lower drug costs, has also weighed in on the insulin debate. Former Commissioner Scott Gottlieb, MD, stated in response to the statutory mandate of the Biologics Price Competition and Innovation Act that “Starting in March 2020, the approved marketing applications for the small subset of ‘biological products’ such as insulin and human growth hormone...will be deemed to be biologics. Once an interchangeable insulin product is approved and available on the market, it can then be substituted for the reference product at the pharmacy, potentially leading to increased access and significantly lower costs for patients.”
Lastly, anticipating the growing need for insulin biosimilars, Sandoz has offered a solution of its own to higher insulin prices. In December 2018, the company announced its agreement with Chinese drug maker Gan and Lee to commercialize biosimilar insulins to treat patients with type 1 and type 2 diabetes.
Hopefully the inclusion of insulin via an FDA established biosimilar pathway will create a healthier marketplace by lowering insulin prices and improving both patient outcomes and access.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.